State Farm Mutual Automobile Insurance Co. Has $1,677,535,000 Stake in Eli Lilly and Company (NYSE:LLY)

State Farm Mutual Automobile Insurance Co. maintained its position in Eli Lilly and Company (NYSE:LLY) during the first quarter, Holdings Channel reports. The institutional investor owned 19,944,525 shares of the company’s stock at the end of the first quarter. Eli Lilly and comprises 2.4% of State Farm Mutual Automobile Insurance Co.’s investment portfolio, making the stock its 15th largest position. State Farm Mutual Automobile Insurance Co.’s holdings in Eli Lilly and were worth $1,677,535,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Joel Isaacson & Co. LLC boosted its stake in shares of Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock valued at $27,280,000 after buying an additional 9,680 shares during the last quarter. Washington Trust Bank boosted its stake in shares of Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock valued at $872,000 after buying an additional 4,990 shares during the last quarter. Bollard Group LLC boosted its stake in shares of Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock valued at $26,408,000 after buying an additional 8,153 shares during the last quarter. Finally, Sabal Trust CO boosted its stake in shares of Eli Lilly and by 1.2% in the first quarter. Sabal Trust CO now owns 6,400 shares of the company’s stock valued at $538,000 after buying an additional 75 shares during the last quarter. Institutional investors own 75.61% of the company’s stock.

Eli Lilly and Company (LLY) opened at 82.07 on Tuesday. The firm’s 50 day moving average price is $82.99 and its 200 day moving average price is $81.53. The stock has a market cap of $86.58 billion, a price-to-earnings ratio of 35.51 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the previous year, the business posted $0.86 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Equities analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.53%. Eli Lilly and’s dividend payout ratio is currently 90.04%.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/08/08/state-farm-mutual-automobile-insurance-co-has-1677535000-stake-in-eli-lilly-and-company-nyselly.html.

Several analysts have recently issued reports on the company. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Friday. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a research note on Friday. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a research note on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. cut Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a research note on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and an average target price of $88.27.

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the sale, the insider now owns 124,265,804 shares in the company, valued at approximately $10,491,761,831.72. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares in the company, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock worth $55,845,287 in the last quarter. 0.20% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

two × 5 =